tbuckley/cabot-search huggingface dataset:
Synchronization of Human Diploid Cells by Fluorodeoxyuridine. The First Ten Minutes of Synthesis in Female Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Jean H. Priest, Judith E. Heady, Robert E. Priest
Journal: JNCI Journal of the National Cancer Institute (1967)

Partial synchronization of human fetal diploid cells was accomplished with 5-fluoro-2′-deoxyuridine (FUDR) followed by addition of exogenous thymidine (TDR). A maximum of 75% of cells were in DNA synthesis (S) following this synchronization procedure, as compared to 30% for asynchronous cells. Optimal synchronization was obtained with 0.1 μg/ml of FUDR for 20 hours. Shortening of the S period by FUDR is suggested. The partial synchrony produced by FUDR block and TDR reversal was lost before completion of a cell cycle. Synchronization by FUDR was used to study the chromosome labeling patterns in human female fetal-diploid cells exposed to 3H-TDR during the first 10 minutes of S. Approximately 60% of metaphases collected at next division after labeling contained an unlabeled C group chromosome. It ranged in total length between the longer and the shorter chromosomes of the C group and was presumed to be an unlabeled X chromosome. No other chromosomes were consistently unlabeled during the first 10 minutes of S.
Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: Clinical evidence of incomplete cross-resistance
Authors: A. Falcone, C. Cianci, E. Pfanner, M. Bertuccelli, I. Brunetti, M.P. Muttini, F. Dargenio, S. Ricci, P.F. Conte
Journal: Annals of Oncology (1994)
S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i>-mutant metastatic colorectal cancer (mCRC).
Authors: Scott Kopetz, Shannon McDonough, Van Karlyle Morris, Heinz-Josef Lenz, Anthony M. Magliocco, Chloe Evelyn Atreya, Luis A. Diaz, Carmen Joseph Allegra, Christopher Hanyoung Lieu, S. Gail Eckhardt, Thomas John Semrad, Kimberly Kaberle, Katherine Guthrie, Howard S. Hochster
Journal: Journal of Clinical Oncology (2015)

TPS790 Background: BRAF V600 mutations are associated with inferior survival and objective responses to the mutated BRAF inhibitor vemurafenib in patients with mCRC. Blockade of BRAF V600 by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. In murine models of BRAF V600 mCRC, the addition of irinotecan to vemurafenib and cetuximab leads to greater anti-tumor activity. Recent phase I studies with the combination of BRAF and EGFR inhibition resulted in response rates substantially higher than either agent alone, with objective responses in 4 of 8 BRAF V600 mCRC patients treated with vemurafenib, cetuximab, and irinotecan. Methods: The SWOG 1406 trial (NCT 02164916) is a randomized phase II study of irinotecan (180 mg/m 2 IV every 14 days) and cetuximab (500 mg/m 2 IV every 14 days) with or without vemurafenib (960 mg PO twice daily). Eligible adult patients have histologically confirmed colorectal adenocarcinoma with metastatic disease. Tumors must have a BRAF V600 mutation and be wild-type for KRAS and NRAS. BRAF testing may be conducted using any CLIA-compliant lab. Alternatively, screening can be provided through a central lab. Patients must have received one or two prior systemic regimens for unresectable locally advanced or metastatic disease and must not have received anti-EGFR agents. Prior treatment with irinotecan is allowed. Patients randomized to the control arm may crossover to the experimental arm at progression. Target enrollment is 78 patients. The primary endpoint is PFS. Optional participation in a co-clinical trial will be offered in selected sites whereby patients’ biopsies will be used to establish patient-derived xenografts to study correlations between patient and PDX with respect to treatment responses and mechanisms of treatment resistance. This trial has support from all adult cooperative groups and utilizes the Central IRB to facilitate study initiation. Conclusions: mCRC patients harboring BRAF V600E mutations may benefit from EGFR and BRAF blockade. We encourage screening for the BRAF mutation early in the course of metastatic disease therapy and for second line therapy on this trial. Clinical trial information: NCT 02164916.
Suppressive Effect of Potassium on Renin Release
Authors: Masaru Maebashi, Yukio Miura, Kaoru Yoshinaga
Journal: Circulation (1968)

Oral administration of potassium chloride to normal subjects and patients with primary aldosteronism had no effect on plasma renin activity. When potassium chloride was given orally to patients with renovascular hypertension, plasma renin activity decreased markedly as compared with the control values. Moreover, an increase in plasma renin activity induced by sodium restriction or diuretics ad-ministration to normal volunteers was prevented by potassium supplement. From these findings it appears that potassium loading suppresses renin release by the kidney. This suppressive effect of potassium on renin release would possibly be mediated through the feedback mechanism of increased aldosterone secretion produced directly by potassium administration.
Effect of Intestinal Microflora Suppression on Liver Carcinogenicity of Dimethylnitrosamine in Syrian Hamsters: Brief Communication 2
Authors: Lori A. Love, Alain Pelfrene, Humberto Garcia
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Effect of Intestinal Microflora Suppression on Liver Carcinogenicity of Dimethylnitrosamine in Syrian Hamsters: Brief Communication Get access Lori A. Love, Lori A. Love Search for other works by this author on: Oxford Academic PubMed Google Scholar Alain Pelfrene, Alain Pelfrene Search for other works by this author on: Oxford Academic PubMed Google Scholar Humberto Garcia Humberto Garcia Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Pages 1835–1836, https://doi.org/10.1093/jnci/58.6.1835 Published: 01 June 1977 Article history Received: 24 May 1976 Revision received: 09 December 1976 Accepted: 21 December 1976 Published: 01 June 1977
Intracytoplasmic sperm injection
Authors: W. Buckett, I. Aird, M. Luckas, C. Kingsland, I. Lewis-Jones, P. Howard
Journal: BMJ (1996)

explicable by Guus A de Jonge and Adele C Engelberts's comments on secondary sleeping position, since the proportion of boys among infants found in the prone position was 53/77 (69%) in the cases and 28/45 (62%) in the con- trols, in the side position 22/43 (51%) and 41/92 (45%) respectively, and in the supine position 36/67 (54%) and 311/618 (50%) respectively.Thus among the babies who died more boys than girls rolled from their side to prone during the final sleep.
Intracytoplasmic Type A Particles in Viper Spleen Cells2
Authors: Philip D. Lunger, H Fred Clark
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Intracytoplasmic Type A Particles in Viper Spleen Cells Get access Philip D. Lunger, Philip D. Lunger Search for other works by this author on: Oxford Academic PubMed Google Scholar H Fred Clark H Fred Clark Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 3, March 1977, Pages 809–811, https://doi.org/10.1093/jnci/58.3.809 Published: 01 March 1977 Article history Received: 02 June 1976 Accepted: 07 September 1976 Published: 01 March 1977
The effect of haloperidol on stuttering
Authors: P B Rosenberger, J A Wheelden, M Kalotkin
Journal: American Journal of Psychiatry (1976)

Haloperidol was compared with placebo in the treatment of 8 young adult stutterers in a double-blind crossover study involving 6 sequential observations over periods of 6 or 12 weeks. The drug was found to have a significant effect on the percentage of time subjects were dysfluent but not on the number of dysfluencies per minute. The authors discuss possible reasons for this finding.
Prognostic Factors in the Initial Response to Therapy by Patients With Advanced Breast Cancer 2
Authors: Stephen L. George, Barth Hoogstraten
Journal: JNCI Journal of the National Cancer Institute (1978)

Identification of important prognostic factors with respect to the patient's initial response to therapy was made from a set of 25 covariates available on 281 patients with advanced breast cancer. Since the patients studied were all participants in a randomized clinical trial that involved three different treatment regimens (repeated weekly treatment of a combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone; intermittent treatment of the same preceding five drugs given in 5-day courses every 4 weeks; or treatment every 3 weeks with adriamycin as a single agent), the effect of these treatments on the selection of important covariates was assessed. Although some evidence indicated that the set of important covariates differed by treatment, the differences were not strong enough to be of practical importance. Non-Caucasian patients did poorly on all regimens with a response rate of only 31% compared to 62% for Caucasian patients. The covariates of major prognostic importance for Caucasians were: disease-free interval, liver involvement, and performance status. Ambulatory patients with long disease-free intervals and no liver involvement had the best prognosis. After adjustments were made for these three covariates, the remaining covariates (such as menopausal status, bone involvement, number of metastatic sites, and duration of metastatic disease) were not significantly related to response. As reported earlier, the treatment effect was significant, even after adjustments were made for the important covariates.
Graphene Oxide‐Copper Nanocomposite‐Coated Porous CaP Scaffold for Vascularized Bone Regeneration via Activation of Hif‐1α
Authors: Wenjie Zhang, Qing Chang, Ling Xu, Guanglong Li, Guangzheng Yang, Xun Ding, Xiansong Wang, Daxiang Cui, Xinquan Jiang
Journal: Advanced Healthcare Materials (2016)

Graphene has been studied for its in vitro osteoinductive capacity. However, the in vivo bone repair effects of graphene‐based scaffolds remain unknown. The aqueous soluble graphene oxide‐copper nanocomposites (GO‐Cu) are fabricated, which are used to coat porous calcium phosphate (CaP) scaffolds for vascularized bone regeneration. The GO‐Cu nanocomposites, containing crystallized CuO/Cu 2 O nanoparticles of ≈30 nm diameters, distribute uniformly on the surfaces of the porous scaffolds and maintain a long‐term release of Cu ions. In vitro, the GO‐Cu coating enhances the adhesion and osteogenic differentiation of rat bone marrow stem cells (BMSCs). It is also found that by activating the Erk1/2 signaling pathway, the GO‐Cu nanocomposites upregulate the expression of Hif‐1α in BMSCs, resulting in the secretion of VEGF and BMP‐2 proteins. When transplanted into rat with critical‐sized calvarial defects, the GO‐Cu‐coated calcium phosphate cement (CPC) scaffolds (CPC/GO‐Cu) significantly promote angiogenesis and osteogenesis. Moreover, it is observed via histological sections that the GO‐Cu nanocomposites are phagocytosed by multinucleated giant cells. The results suggest that GO‐Cu nanocomposite coatings can be utilized as an attractive strategy for vascularized bone regeneration.
Follow-up of abstinent and nonabstinent alcoholics
Authors: E Gottheil, C C Thornton, T E Skoloda, A I Alterman
Journal: American Journal of Psychiatry (1982)

Despite differences in samples and designs, follow-up studies of alcoholic patients by the Rand Corporation, the state of Oklahoma, and the Veterans Administration (VA) revealed more similarities than differences in outcome and relapse. In the VA study at 6, 12, and 24 months' follow-up, it was found that drinking status and psychosocial adjustment were significantly correlated, the percentage of patients drinking moderately varied from 33% to 47% and did not decrease over time, and the percentage of patients in remission remained constant at 55% over the 2-year period. These data appear to support the inclusion of moderate drinking in the definition of remission.
PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression
Authors: Christelle Vincent-Fabert, Nadine Platet, Amelle Vandevelde, Mathilde Poplineau, Myriam Koubi, Pascal Finetti, Guillaume Tiberi, Anne-Marie Imbert, François Bertucci, Estelle Duprez
Journal: Blood (2016)
Chromosomes of the Walker 256 Rat Mammary Carcinoma: Observations on Primary and Metastatic Tumors of a New Subline With a Pseudodiploid Karyotype&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: S F Nicholson, O G Thurston, P Bowen
Journal: JNCI Journal of the National Cancer Institute (1968)
An Alkylating Agent-Globulin Conjugate With Both Al-kylating and Antibody Activity2
Authors: J. H. Linford, G. Froese, I. Berczi, L. G. Israels
Journal: JNCI Journal of the National Cancer Institute (1974)

The biologic alkylating agentTrenimon (2,3,5-trisethylenimino-1,4-benzoquinone) bound readily to partially reduced proteins which included immunoglobulins. The complex retained antibody activity, was an active alkylating agent, and possessed immunologically specific cytotoxicity. These results indicate that it may be possible to prepare conjugates of Trenimon with protein carriers targeted for specific cells.
SP0034 Eular Points to Consider for Reporting, Detecting and Screening Risk Factors of Selected Comorbidities in Chronic Inflammatory Rheumatic Diseases in Clinical Practice
Authors: M. Dougados
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Comorbidities are increasingly important when considering the management of patients with chronic inflammatory rheumatic diseases. Such importance is not only due to the aging of our patients but also the recognized increased risk of some comorbidities such as cardiovascular diseases because of the disease itself or its treatment. <h3>Objectives</h3> To propose a standardized way of reporting and detecting commonly observed comorbidities in chronic inflammatory rheumatic diseases. <h3>Methods</h3> Under the umbrella of EULAR, a task force was composed of rheumatologists, fellows, epidemiologists, health professionals and patients. Such task force had to define clearly the main objectives of this initiative including the target population, the selection of comorbidities to be adressed. the method to report and/or to detect and/or to prevent such comorbidities. The methodology used both a systematic literature research and a consensual approach. <h3>Results</h3> The task force concluded the following: –The target population is defined by patients suffering from chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis including psoriatic arthritis, connective tissue disorders such as systemic lupus erythematosus, microcristalline polyarticular disease; the potential inclusion of polyarthrosis was discussed. –The context is defined by the fact that the proposals would be used in daily practice by rheumatologists but also by health professionals such as nurses. A potential future proposal to be used by the patients (e.g. self-administered comorbidity questionnaire) was discussed. –The selected comorbidities are cardiovascular diseases, malignancies, infections, osteoporosis, gastrointestinal diseases and depression. –For each comorbidity, the following items were proposed: How to report a specific comorbidity? (e.g. breast cancer), how to detect a specific comorbidity? (e.g. mammography for breast cancer), how to prevent such comorbidity?(e.g. hypertension for cardiovascular disease). –The final proposals are presented in a such a way that they will be easily implemented in daily practice. <h3>Conclusion</h3> Such initiative should facilitate the standardization and therefore should improve the management of comorbidities in patients suffering from chronic inflammatory rheumatic diseases. <h3>Disclosure of Interest</h3> None declared
A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)
Authors: Jesus Berdeja, Michael Savona, Joseph R Mace, Lowell Hart, James Essell, Rami Owera, Edward Arrowsmith, Ian Flinn
Journal: Blood (2013)
A Case of Sphenoid Sinus Metastasis in Hepatocellular Carcinoma
Authors: Tae Hoon Lee, Vikram Rangan, Hicham Khallafi
Journal: Hepatology (2016)

Sphenoid sinus metastasis from hepatocellular carcinoma (HCC) has been reported only rarely. We present a case of solitary sphenoid sinus metastasis of a 2.7 × 2.3 cm single HCC lesion. (H epatology 2016;63:2050‐2053)
Gonadotropin Interpretation in a 25-Year-Old Man
Authors: James A. Kashanian, Robert E. Brannigan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resistance training in patients with radically treated respiratory cancer: mature results of a multi-centre randomised phase 3 trial (REINFORCE)
Authors: Jan Van Meerbeeck, Bihiyga Salhi, Christel Haenebalcke, Sylvia Perez-Bogerd, May D Nguyen, Thomas Malfait, Karim Vermaelen, Veerle Surmont, Georges Van Maele, Roos Colman, Eric Derom
Journal: Journal of Thoracic Oncology (2013)
Three-Day-Old Boy With Palmar Pustules
Authors: Vikash Oza, Sarah Asch, Erin F. Mathes
Journal: JAMA Pediatrics (2016)

A 3-day-old full-term male infant was seen for possible systemic infection in the setting of newly noted numerous right palmar pustules and pustules scattered on his face, trunk, diaper area, and extremities. What is your diagnosis?
Breakdown of Gross Virus-Induced Tolerance in Rats by Inoculation of Lymphoid Cells 2
Authors: Noritoshi Takeichi, Noboru Kuzumaki, Takao Kodama, Hiroshi Kobayashi
Journal: JNCI Journal of the National Cancer Institute (1974)

The inoculation, in rats, of spleen and lymph node cells or thymus cells from syngeneic immune donors destroyed tolerance induced by Gross virus (GY). When tolerance was abrogated, the rats produced the cytotoxic antibody and resisted transplantation to GY-induced tumor (WGT-4) cells; none developed primary thymomas. The cytotoxicity test proved that the cells acquiring GY-specific cell-surface antigen were in the thymus of tolerant rats and disappeared after inoculation of immune cells. Histologically, thymus atrophy with depleted lymphocytes and enlarged spleen with proliferating reticular cells were observed 12–15 days after immune cell inoculation. These lesions disappeared completely by the 21st day. The mechanism of abrogating tolerance is considered the immunologic interaction between inoculated cells and those acquiring a new cellular antigen in the host.
Duration of Ebola virus RNA persistence in semen of survivors: population-level estimates and projections
Authors: Rosalind M Eggo, Conall H Watson, Anton Camacho, Adam J Kucharski, Sebastian Funk, W John Edmunds
Journal: Eurosurveillance (2015)

Ebola virus can persist in semen after recovery, potentially for months, which may impact the duration of enhanced surveillance required after interruption of transmission. We combined recent data on viral RNA persistence with weekly disease incidence to estimate the current number of semen-positive men in affected West African countries. We find the number is low, and since few reported sexual transmission events have occurred, the future risk is also likely low, although sexual health promotion remains critical.
Daily G-CSF (filgrastim) and a Single Dose Of Pegylated G-CSF (pegfilgrastim) After Chemotherapy Result In Different Kinetics Of Circulating Hematopoetic Progenitors: Implication For Potential Stem Cell Harvesting
Authors: Felix Schaub, Birgit Federmann, Lothar Kanz, Robert Möhle
Journal: Blood (2013)
Elucidating the role of the host genome in shaping microbiome composition
Authors: Emily R. Davenport
Journal: Gut Microbes (2016)

A major goal of microbiome research is to identify the factors that determine bacterial composition within and upon a host. Environmental factors are thought to play a large role, such as diet in determining gut microbiome composition and moisture in determining skin microbiome composition. The role of host genetics, however, has been a source of debate in the literature. Recently, we examined the association of host genetics with human gut microbiome composition in the Hutterites, a population that lives and eats communally. We identified heritable bacterial taxa and host genetic loci associated with their abundances. In this addendum, I put these results into a broader context along with other recent studies of microbiome heritability, and synthesize common themes that appear across organisms and tissues, such as the relatively small extent genetics plays compared to environment and the role of host genetic variation in immune response and barrier integrity.
CSIG-07EGFRvIII MEDIATED TRANSACTIVATION OF RECEPTOR TYROSINE KINASES IN GLIOMA: MECHANISM AND THERAPEUTIC IMPLICATIONS
Authors: Terrance Johns, Sam Greenall, Jacqui Donoghue, Tim Adams
Journal: Neuro-Oncology (2015)

A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly expressed in glioma, an incurable brain cancer.EGFRvIII is tumorigenic, in part, through its transactivation of other receptor tyrosine kinases (RTKs). Preventing the effects of thistransactivation could form part of an effective therapy for glioma; however, the mechanism by which the transactivation occurs isunknown. Focusing on the RTK MET, we show that MET transactivation in U87MG human glioma cells in vitro is proportional toEGFRvIII activity and involves MET heterodimerization associated with a focal adhesion kinase (FAK) scaffold. The transactivationof certain other RTKs was, however, independent of FAK. Simultaneously targeting EGFRvIII (with panitumumab) and thetransactivated RTKs themselves (with motesanib) in an intracranial mouse model of glioma resulted in signiﬁcantly greater survivalthan with either agent alone, indicating that cotargeting these RTKs has potent antitumor efﬁcacy and providing a strategyfor treating EGFRvIII-expressing gliomas, which are usually refractory to treatment.Oncogene advance online publication, 9 February 2015; doi:10.1038/onc.2014.448INTRODUCTIONHigh-grade glioma (HGG), often simply called glioma, is amalignant brain tumor that is incurable because of its relativelyrefractory nature to the standard of care, which involves surgicalresection, radiotherapy and the chemotherapeutic temozolomide.Glioma has been classiﬁed into four distinct molecular subtypes,each characterized by a set of molecular traits.